[Controlled clinical study on efficacy of fixed-dose compounds rifater/rifinah in antituberculous chemotherapy].

Abstract

OBJECTIVE:

To assess antituberculous efficacy, patients' compliance and application perspective of fixed-dose compounds rifater/rifinah in China.

METHOD:

Three hundred eight new smear positive pulmonary tuberculosis patients were randomly allocated with a ratio of 2 to 1 into treatment group (227 cases, receiving 2RIFATER/4RIFINAH regimen) and controls (81 cases, 2HRZ/4HR) for observation.

RESULT:

The sputum negative conversion rates at the 2nd month in the treatment group and the controls were 91.2% and 86.4% respectively, and at the end of the chemotherapy 98.7% and 97.5%. Chest radiography showed remarkable improvement. The resolution of pulmonary lesions in the treatment group and the controls accounted for 95.2% and 93.8% respectively, with cavity closure rates of 68.6% in the treatment group and 67.9% in the controls. The drug adverse reaction rates were 8.9% in both groups, and the default rates were 4.3% and 7.8% respectively.

CONCLUSION:

Fixed-dose compounds rifater/rifinah show excellent therapeutic efficacy, safety and compliance in antituberculous chemotherapy, which could be recommended for wider use in tuberculosis control in China.

• Authors: L Zhu, B Yan, W Ma
• Journal: Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases (Zhonghua Jie He He Hu Xi Za Zhi) Vol. 21 Issue 11 Pg. 645-7 (Nov 1998) ISSN: 1001-0939 [Print] China
• PMID: 11477887 (Publication Type: Clinical Trial, English Abstract, Journal Article, Randomized Controlled Trial)

Chemical References

• Antitubercular Agents
• Pyrazinamide
• Isoniazid
• Rifampin

Topics

• Adolescent
• Adult
• Aged
• Antitubercular Agents (therapeutic use)
• Drug Therapy, Combination
• Female
• Humans
• Isoniazid (administration & dosage)
• Male
• Middle Aged
• Pyrazinamide (administration & dosage)
• Rifampin (administration & dosage)
• Tuberculosis, Pulmonary (drug therapy)